DMHA Octodrine.
DMHA Octodrine supplementation for targeted health support. Sympathomimetic stimulant similar to DMAA. Increases energy, focus, and potentially blood pressure and heart rate.
Reviewed March 2026
- Category
- Nootropic
What DMHA Octodrine is, and what it does.
- Does it work
- Human data runs to a single record at Europe PMC, so what is known comes from pharmacology rather than trials. Check with a clinician first if heart rate or blood pressure is a consideration.
- How much to take
- DO NOT TAKE. Products used 100-200mg but this is unstudied.
- Time to feel it
- An indirect sympathomimetic works quickly. Expect the adrenergic pattern, a faster heart rate and a lift in drive, within about 30 to 60 minutes of an oral dose.
- The first dose
- The stimulant effect lands inside about half an hour: raised alertness and drive, with a faster heart rate and narrowed vessels arriving in the same window.
- With regular use
- Nobody has studied weeks of daily use in people. Indirect releasing amines draw on stored noradrenaline, so the same amount produces less response as dosing continues.
- How well tolerated
- This is not well characterised in people, and it raises heart rate and blood pressure by mechanism. Check with a clinician first, and don't stack it with other stimulants.
- How it feels
- Sharp, fast alertness with a pushed heart rate. Some people find it clean and driven, others find it tips into jitteriness and a hard comedown.
- The overlooked benefit
- It has no catechol ring, so the enzyme that clears adrenaline-like molecules cannot act on it. That is why its effect runs longer than a catecholamine of similar size.
50 to 100mg a day is where DMHA Octodrine works.
Source: FDA compliance concerns; no peer-reviewed human trials
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
DMHA Octodrine has emerging evidence. Based on 1+ studies.
- Effective stimulantPharmacological mechanism similar to DMAA
- Well tolerated in supplementsNo safety studies, FDA warnings
- Natural occurrenceClaims not verified by independent research
Questions people ask about DMHA Octodrine.
- Is DMHA safer than DMAA?
- Unknown. Less studied doesn't mean safer. Similar mechanism suggests similar risks.
- Is it legal?
- Gray area. FDA has warned companies. May be removed like DMAA was.
- Why do companies use it?
- To replace DMAA. Looking for potent stimulants that aren't yet banned.
- Any deaths associated?
- Less documented than DMAA, but that may be due to less use, not better safety.
- What are the names?
- DMHA, octodrine, 2-aminoisoheptane, 2-amino-6-methylheptane. Same compound.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Octodrine is a sympathomimetic amine that raises noradrenergic tone, and caffeine independently raises catecholamine signalling and cAMP persistence. Stacked, their effects on normal heart rate and blood pressure add rather than cancel.
Both raise sympathetic drive by different routes, one by amine release and one by adenosine blockade. Total stimulant load in a pre-workout must be counted across both, since the cardiovascular effect is additive.
Octodrine works partly by promoting release of stored catecholamines. Tyrosine is the amino acid precursor those catecholamines are built from, so it supports the pool being drawn on.
Yohimbine blocks the presynaptic alpha-2 autoreceptor that normally restrains norepinephrine release, while an indirect sympathomimetic amine displaces norepinephrine into the synapse. The two arrive at the same endpoint from different directions, so cardiovascular effects run together. No trial of this specific pair was identified. Flagged as an additive interaction on established class grounds.
Most green tea extracts carry residual caffeine, so pairing one with a sympathomimetic amine raises total stimulant exposure beyond what the label suggests for either alone. The additive part is the caffeine, not the catechins. Whether EGCG itself interacts with octodrine has not been studied. Read the caffeine content of the extract before assuming the pairing is neutral.
Alpha GPC supplies choline for acetylcholine synthesis, a separate transmitter system from the adrenergic one an aliphatic amine acts through. Formulators combine the two so the blend touches both systems. No study has tested alpha GPC with octodrine. The pairing is convention plus non-overlapping mechanism, nothing stronger.
Taurine acts at inhibitory glycine and GABA-A sites and serves as an intracellular osmolyte, which is why it appears in many stimulant energy formulas. Its presence does not reduce the adrenergic drive of an amine like octodrine. Any perceived smoothing is subjective and unmeasured for this pair. The mechanism is established, the combination effect is not.
Beta alanine raises muscle carnosine over weeks of daily dosing and has no adrenergic action, so it shares a product with octodrine rather than a mechanism. The pairing is about what a pre-workout is expected to contain. No interaction between the two has been described. Recorded as formulation practice so the row is not mistaken for pharmacology.
Magnesium restrains catecholamine release and contributes to normal vascular smooth muscle relaxation, which places it in the opposite direction from an adrenergic releasing amine. Adequate magnesium status is part of normal cardiovascular regulation whatever else a formula contains. No study has tested magnesium against octodrine specifically. The direction comes from established physiology.
Beta-adrenergic stimulation activates the sodium-potassium pump and shifts potassium from plasma into cells, a well-characterised response to any adrenergic agent. That makes normal potassium status part of the physiological context for a sympathomimetic amine. The relationship is established pump physiology, not a tested combination with octodrine. It is a mechanistic note rather than a benefit claim.
Rhodiola rosea extract appears in the same energy and focus matrices as sympathomimetic amines, so the two co-occur in products. There is no characterised pharmacological interaction between them. Both are discussed in monoamine terms, which is a reason to note the pairing rather than assume it is inert. Lowest confidence band applies.
Talk to a doctor before taking DMHA Octodrine if any of these apply to you: Banned/controlled substance, Not a legal supplement, Dangerous - FDA enforcement action. These are flags to check first, not effects DMHA Octodrine is known to cause.
Not medical advice. Show the label to your pharmacist.What DMHA Octodrine actually does.
Octodrine is 2-amino-6-methylheptane, an aliphatic (non-aromatic) amine, and aliphatic amines of this class lack the catechol ring that catechol-O-methyltransferase acts on, which is why such amines are not substrates for that enzyme.
Indirect sympathomimetic amines act by entering the presynaptic neuron through the norepinephrine transporter and displacing stored norepinephrine into the synapse rather than binding adrenergic receptors themselves.
Raised synaptic norepinephrine produces the standard adrenergic pattern: increased heart rate through beta-1 receptors, vascular constriction through alpha-1 receptors and airway smooth muscle relaxation through beta-2 receptors.
A primary aliphatic amine is a weak base, so it exists almost entirely as the protonated cation at gastric and plasma pH, and the free base is a volatile oil while the hydrochloride salt is a crystalline solid.
Where DMHA Octodrine comes from.
This is a made-in-a-reactor molecule, not something pressed out of a plant. Chemists build a short branched carbon chain, attach an amine group, distil it, then turn it into a salt so it becomes a dry powder that can be weighed. Some labels name a plant as the source. Analysts have questioned whether the plant actually contains it, so the plant name on a label is not evidence of where the amine came from.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
The 6-methylheptane backbone comes from ordinary organic feedstocks, not from a plant harvest.
The amino group is introduced onto the branched alkyl chain by standard amination chemistry, giving the racemic primary amine.
The volatile free base is separated and purified by distillation.
Treatment with hydrochloric acid gives the crystalline hydrochloride, which is dried and milled for blending into powders or capsules.
Manufacturing site, synthetic route, whether the label figure refers to the salt or the free base, and whether the lot was assayed for identity are commonly not disclosed.
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.